VIMTALABS · NSE
Vimta Labs Limited
₹603.1
+0.58% (+₹3.5)
Prev. close
₹599.6
Volume
91,341
Delivery %
44.8%
As of
18 Sept 2026
Price history
Vaishali Parekh · Prabhudas Lilladher · 06 Aug 2026
“Recommends buying Vimta Labs for intraday trading at ₹656.50, targeting ₹690 with a stop loss at ₹642.”
Entry ₹656.5Target ₹690 (+5.1%)Stop ₹642 (-2.2%)R:R 2.3:1Stopped out · 06 Aug 2026
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Recommends buying Vimta Labs for intraday trading at ₹656.50, targeting ₹690 with a stop loss at ₹642.” | Vaishali ParekhPrabhudas Lilladher | Vimta Labs | NOT GRADED | ||||
“Recommends buying Vimta Labs for intraday trading at ₹656.50, targeting ₹690 with a stop loss at ₹642.” This call couldn't be objectively graded against market data. | |||||||
Fundamentals
About Vimta Labs Limited
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies. It also provides food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, and regulators; and a testing laboratory for water, alcoholic, and non-alcoholic beverages. In addition, the company offers environmental regulatory services, such as impact assessments and post project monitoring, to various industries, including power, infrastructure, cement, oil and gas, and mining, etc.; and EMI/EMC testing for electronic and electrical products/components. It provides solutions to agriculture, biologics and biosimilars, home and personal care, medical device, specialty chemicals, food, electrical and electronics, nutraceuticals, water and beverages, pharmaceuticals, crop care, environment, health and safety, and packaging industries. Vimta Labs Limited was founded in 1984 and is headquartered in Hyderabad, India.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Dr. Sivalinga Prasad Vasireddi
Headquarters
Hyderabad
Employees
1,384
Website
vimta.comExchange
View on NSE ↗Key stats
Market cap
₹2,695.85 Cr
P/E ratio (TTM)
33.7
Dividend yield
0.33%
EPS (TTM)
₹17.87
Beta (1Y · daily vs NIFTY 50)
1.33
Beta (5Y · monthly vs NIFTY 50)
0.71
Shares float
1.42 Cr
EPS · quarter ended Jun 2026
₹4.66
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹210.68 Cr | ₹278.28 Cr | ₹318.19 Cr | ₹288.60 Cr | ₹343.98 Cr | ₹407.29 Cr | |
| EBITDA | ₹53.79 Cr | ₹80.51 Cr | ₹98.36 Cr | ₹98.22 Cr | ₹126.12 Cr | ₹148.24 Cr |
| ₹21.26 Cr | ₹41.33 Cr | ₹48.17 Cr | ₹41.01 Cr | ₹67.34 Cr | ₹77.51 Cr | |
| Diluted EPS | ₹4.84 | ₹9.16 | ₹10.68 | ₹9.12 | ₹14.93 | ₹17.4 |
Total expenses (as filed), Employee benefit expense, Other expenses, Interest expense, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹274.36 Cr | ₹307.20 Cr | ₹362.33 Cr | ₹394.47 Cr | ₹466.53 Cr | ₹562.23 Cr | |
| — | ₹19.34 Cr | ₹14.99 Cr | ₹19.19 Cr | ₹8.52 Cr | ₹3.33 Cr | |
| Stockholders' equity | ₹194.38 Cr | ₹233.98 Cr | ₹281.79 Cr | ₹314.12 Cr | ₹378.85 Cr | ₹456.87 Cr |
Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹37.18 Cr | ₹59.07 Cr | ₹87.94 Cr | ₹60.89 Cr | ₹94.05 Cr | ₹147.14 Cr | |
| Investing cash flow | ₹-31.92 Cr | ₹-37.85 Cr | ₹-57.26 Cr | ₹-76.05 Cr | ₹-75.54 Cr | ₹-129.67 Cr |
| ₹-4.57 Cr | ₹-16.61 Cr | ₹-10.98 Cr | ₹-1.90 Cr | ₹-16.12 Cr | ₹-10.35 Cr | |
| Capital expenditure | ₹-33.09 Cr | ₹-38.72 Cr | ₹-49.81 Cr | ₹-76.57 Cr | ₹-79.49 Cr | ₹-99.80 Cr |
| End cash position | ₹6.19 Cr | ₹10.80 Cr | ₹30.50 Cr | ₹13.44 Cr | ₹15.84 Cr | ₹22.97 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Sep 22(5Q) | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24–Sep 24(2Q) | Dec 24 | Mar 25 | Jun 25–Jun 25(2Q) | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 37.46% | 37.25% | 37.24% | 37.23% | 37.01% | 36.98% | 36.92% | 36.89% | 36.76% | 36.70% | 36.67% | 35.99% | 35.90% | 35.85% | 35.67% |
| Public | 62.54% | 62.75% | 62.76% | 62.77% | 62.99% | 63.02% | 63.08% | 63.11% | 63.24% | 63.30% | 63.33% | 64.01% | 64.10% | 64.15% | 64.33% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Vimta Labs Limited | ₹2,680.20 Cr | ₹603.1 | 33.6 | 5.87 | 17.0% | 0.01 | +18.4% | -23.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 29
Concall transcripts
Show all 11
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
VIMTALABS: Q1 FY27 saw higher revenue and profit, with EPS up and a one-time gratuity expense recognized
TradingView · 2 months ago